Dr. Wai Liu, Ph.D.

Dr. Wai Liu received his PhD in Medical Oncology and Clinical Pharmacology from St Bartholomew’s Hospital, University of London, in 2001 and lead small research groups as a research fellow at St Bartholomew’s and at the Institute of Cancer Research.

Dr Liu joined St George’s in 2007, working with Professor Angus Dalgleish investigating the role of the immune modulatory drugs IMiDs as anticancer agents. During this time, he developed models to assess the effect of combining chemotherapies with other treatment modalities as a way of enhancing activity.

Dr. Liu has worked in a cancer research environment for over twenty years. He is a prominent scientist in the field of cannabinoid research, which is an area he has actively engaged for over fifteen years. His team was the first to demonstrate a benefit in combining cannabinoids and irradiation in models of brain cancer.

Other interests of Dr. Liu have been to develop new combination strategies that utilize re-purposed agents. These have included naltrexone, artemisinin and the IMiDs. He has also investigated ways of enhancing anticancer activity by modifying the pathological associations between immune and tumor cells by using immune-targeting drugs.

He is a Senior Research Fellow at the Institute of Infection and Immunity of St. George’s University of London, has over 50 publications in the field of cancer research, and worked in collaborations with pharma including GW Pharma, Celgene, AstraZeneca and Novartis to develop new agents and to perform pre-clinical work; a number of these has continued successfully into Phase I and II trials. Dr. Liu welcomes questions and can be contacted via his twitter account: @wai_liu

To view his bio, click on Dr. Wai Liu’s Profile

To view his published articles, click on Dr. Wai Liu’s Profile